IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ...
IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...
IRVINE, Calif. - Axonics, Inc. (NASDAQ:AXNX), a medical technology company, has announced today that it received approval from Australia's Therapeutic Goods Administration (TGA) to market its Axonics ...
The Axonics F15 recharge-free SNM system's functional life has been validated for over 15 years at typical stimulation parameters and more than 2 decades at lower energy settings. INS volume: 10 cubic ...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S ...
Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...
Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback